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Summary We investigated how residual tumour burden after cytoreductive surgery was related to the
occurrence of acute and delayed nausea and vomiting in 101 ovarian cancer patients receiving their first
chemotherapy course. The anti-emetic treatment included ondansetron combined with dexamethasone or
placebo. After chemotherapy all patients received ondansetron only for 5 days. Two categories of tumour
burden (TB) were formed according to the diameter of the greatest residual tumour (<2 cm=minimal TB and
>2 cm=large TB). Self-reports of nausea and vomiting were obtained for 15 days. Other potential predictor
variables were assessed and included in multivariate analyses. Patients with large compared with minimal TB
had more delayed emesis, especially on days 2-7. They also had more acute nausea. The aggravating effect
associated with large residual TB was more evident in patients >55 years. During the second week after the
chemotherapy the occurrence of nausea was higher in patients >55 years than in those <55 years. This was
seen primarily in patients with large residual TB. Predictors for no delayed emesis at all were anti-emetic
treatment with dexamethasone, minimal tumour burden, low neuroticism and no history of motion sickness.
The increased risk of 'persistent' delayed nausea and vomiting seen in older patients with large tumour burden
may have important clinical implications and warrants further attention.
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Delayed emesis is a major problem for many patients. It
starts by definition 24 h after the beginning of the
chemotherapy and may last for several days (Joss et al.,
1994; Sorbe et al., 1994). As opposed to the model for acute
emesis with an assumed single dominating mechanism
(release of 5-HT acting on abdominal 5-HT3 receptors
resulting in activation of vagal afferents), several pathways
have been proposed for delayed nausea and vomiting.
Cerebral oedema, disordered gut function and cell degrada-
tion products are factors suggested as related to delayed
emesis but the empirical evidence for any mechanism is
sparse (Andrews and Davis, 1993).
Identifying predictors for delayed nausea and vomiting
may aid in the understanding of the pathogenesis of the
disorder and in optimising the anti-emetic treatment. The
dose of cisplatin and preceding acute emesis or emesis during
previous cycles have been established as prognostic factors
for delayed emesis (du Bois et al., 1992; Italian Group for
Antiemetic Research, 1994; Roila et al., 1991). High
pretreatment noradrenaline excretion as well as low cortisol
excretion have been associated with nausea or vomiting
occurring more than 24 h after the start of the chemotherapy
(Fredrikson et al., 1992, 1994; Hursti et al., 1993). In some
studies gender has been reported to affect delayed nausea
(Kaizer et al., 1994; Roila et al., 1991) or vomiting (du Bois
et al., 1992) but in other reports no significant association
was found (Italian Group for Antiemetic Research, 1994;
Carmichael et al., 1994; Gandara et al., 1993; Lindley et al.,
1989). One study reported an association between previous
motion sickness and delayed nausea (Kaizer et al., 1994).
Summing up, only a few patient characteristics have so far
been found to modify delayed nausea and vomiting.
However, most of the studies accomplished were not
primarily designed to identify predictors of delayed emesis.
In the light of the suggested mechanisms for delayed
emesis, the study of the potential influence of residual tumour
burden on chemotherapy-induced nausea and vomiting is
warranted. The aim of the present study was to investigate
this relation during a 15 day assessment period starting from




A total of 101 chemotherapy-naive ovarian cancer patients
referred to the Department of Gynaecological Oncology,
Radiumhemmet, participated in the study. Exclusion criteria
included severe concurrent disease, gastrointestinal obstruc-
tion, vomiting and/or having received anti-emetics within
24 h before the start of chemotherapy. All patients had
undergone primary cytoreductive surgery about 1 month
earlier. Residual tumour burden after completed surgery was
estimated by the surgeon. Information about the residual
tumour burden was gathered from the surgery records
without knowledge of the patients' scoring of nausea and
vomiting. Tumour burden was first classified into four
categories according to the diameter of the greatest residual
tumour: (1) from no visible tumour to less than 2 cm (n =60);
(2) 2-5 cm (n = 11); (3) 5 -10 cm (n =6); and (4) larger than
10 cm (n = 24). In the statistical analyses the first group
(<2 cm), termed 'minimal tumour burden' was compared
with the rest of the patients (,>2 cm), termed 'large tumour
burden'. The median age was 54 years (range 18-76 years).
The chemotherapy included cisplatin (50 mg m-2) com-
bined with either doxorubicin (50 mg m-2) during a single
day (n = 33) or doxorubicin (40 mg m-2) and melphalan
(0.4 mg kg-') on the day before cisplatin (n =68). As anti-
emetic medication, patients received ondansetron
8 mg i.v. x 3, on both chemotherapy days (applies for the 2
day treatment) and were randomised to combine ondansetron
either with dexamethasone (20 mg i.v. x 1) or placebo given
6 h after the cisplatin infusion was started. Additionally, all
patients received ondansetron (8 mg orally x 3) daily for 5
days after the chemotherapy. Results concerning the anti-
emetic trial (dexamethasone vs placebo) will be reported
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Methods
Nausea and vomiting were self-recorded by the patients daily
starting on the day of cisplatin administration (=day 0) and
continuing on days 1 to 14. Nausea was registered on a four-
grade scale (none, mild, moderate or severe) and vomiting as
the number of emetic episodes. An emetic episode was
defined as a single vomit or retch or any number of
continuous vomits and/or retches. The patients were
instructed to fill in the registration form every morning as
an average estimation of the symptoms during the previous
24 h period. In addition, on arrival at the hospital on the day
before their first chemotherapy course, an assessment of the
patients' functional status and general well-being during the
preceding week was made. The patients were requested to
report, using a 100 mm visual analogue scale (VAS), if they
had been bothered by e.g. nausea, vomiting, sleeping
disorders, pain and anxiety. Additionally 12 aspects of daily
life were investigated with this method.
Some other characteristics previously reported as asso-
ciated with chemotherapy-related nausea and vomiting were
also assessed (Andrykowski and Gregg, 1992; Hursti et al.,
1992, 1994; Martin and Diaz-Rubio, 1990; Morrow, 1985).
These were age, history of nausea and vomiting in general
and in specific situations (motion sickness, nausea during
pregnancy, nausea related to alcohol consumption), trait and
state anxiety (Spielberger et al., 1968), neuroticism (Eysenck
and Eysenck, 1964) and autonomic perception (Borcovec,
1976). The purpose was to identify possible confounding
factors for the findings concerning tumour burden.
Statistics
In the statistical analyses patients with minimal tumour
burden (i.e. <2 cm) were compared with those having large
tumour burden (i.e. 2 cm). Ratio of proportions (RP) was
used to describe the association between the studied factors
and nausea or vomiting. It was calculated as the ratio
between the proportions of patients with no nausea or no
emetic episodes (i.e. complete response) in the groups of
interest. To adjust for the differences in anti-emetic treatment
and the possible confounding effect from another studied
factor, data were stratified and a weighted ratio of
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proportions was computed with a method described by
Ahlbom (1990). Calculation of 95% confidence intervals was
performed based on a variance described by Greenland and
Robins (1985). Ratio of proportions provides a very
comprehensible measure of effect. However, since the
method we used allowed a simultaneous adjustment only
for a limited number of other variables, we also performed
logistic regression analyses with tumour burden, all the
patient characteristics (see Methods) and anti-emetic treat-
ment entered in one block. As a complement to the day-by-
day analyses, we sought to predict the total anti-emetic
response in the entire delayed phase. For that purpose the
outcome was defined as a binary response based on whether
the patient had experienced emetic episodes and nausea,
respectively, during any of the days 1-14). Associations
between tumour burden and other patient characteristics
were analysed by x2 test where continuous variables were
dichotomised by a median-split approach. Prechemotherapy
VAS ratings were analysed by Student's t-test and x2 test.
Results
With the exception of age, groups with minimal compared
with large tumour burden were well balanced concerning
patient and treatment characteristics (all X2(l)< 1.4; NS)
(Table I). Sixty-eight per cent of the patients with large
tumour burden were above the median age (i.e. >55 years) as
compared with 38% among patients with minimal tumour
burden (X2(1)=8.7; P=0.003). Nausea and vomiting were
similar in the groups of patients having received their
chemotherapy on a single day compared with a 2 day
treatment.
Effects on emetic episodes
Figure 1 displays the proportions ofpatients free from emetic
episodes as a function of tumour burden. A quite consistent
trend showing that the prevalence of emetic episodes was
higher among patients with large tumour burden (i.e. >2 cm
in greatest diameter) was observed throughout the assessment
period. Ratios of proportions, adjusted for age and anti-
emetic treatment, were significant for days 3 [RP (with 95%
confidence interval) 1.4 (1.1 -1.9)], 4 [RP 1.2 (1.0-1.4)] and 5
[RP 1.2 (1.0-1.5)]. Restricting the analysis to older (>.55
years) patients revealed an even more marked association
(Figure 2). Ratios of proportions adjusted for anti-emetic
Table 1 Patient and treatment characteristics in groups of patients categorised by the diameter of the greatest
residual tumour (<2 cm vs >2 cm)
Patients with Patients with
Variable tumour<2 cm tumour k2 cm P
Number of patients 60 41
Antiemetics NS
Ondansetron and dexamethasone 34 19
Ondansetron and placebo 26 22
Chemotherapy given on NS
A single day 17 16
Two days 43 25
Age (mean) 51.5 59.1 <0.001
Previous history of (%)
Nausea in general 70 71 N.S.
Vomiting in general 58 54 N.S.
Motion sickness 40 49 N.S.
Nausea during pregnancy 59 47 N.S.
Nausea related to alcohol consumption 12 7 N.S.
Personality (mean scores on the inventories)
State anxiety 45.3 44.6 N.S.
Trait anxiety 35.5 35.7 N.S.
Neuroticism 6.1 5.2 N.S.
Autonomic perception 67.6 63.2 N.S.Impact of tumour burden on emesis
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Figure 1 Proportions of patients free from emetic episodes as a
function of residual tumour burden (see Methods). E, Minimal
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Figure 4 Proportions of patients free from nausea as a function
of age among those having large residual tumour burden. L,
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Days after chemotherapy
Figure 2 Proportions of patients free from emetic episodes as a
function of residual tumour burden among those aged 55 years or
more. O, Minimal tumour and >55 years; *, large tumour and
>55 years.
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Days after chemotherapy
Figure 5 Proportions of patients free from emetic episodes as a
function of residual tumour burden and/or age. O, <55 years
and minimal tumour; *, > 55 years or large tumour; *, >55
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Figure 3 Proportions of patients free from nausea as a function
of age. E], <55 years; *, > 55 years.
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Days after chemotherapy
Figure 6 Proportions of patients free from nausea as a function
of residual tumour burden and/or age. EL, < 55 years and






in notreatment reached significance for days 3 to 7 ranging from
1.2 to 1.5. Among younger patients, the size of the remaining
tumour was not significantly associated with emetic episodes.
A statistically non-significant initial trend for more
frequent emetic episodes in older patients was observed.
Ratio of proportions adjusted for tumour burden and anti-
emetic treatment was 1.4 (0.9-2.2) for the cisplatin day and
1.2 (0.9-1.8) for day 1 after chemotherapy.
The logistic regression analyses with all the predictor
variables entered in one block showed that tumour burden
significantly predicted emetic episodes during days 2-3 and
5-7 (P<0.05) and that the prediction was marginally
significant for day 4 (P=0.07) and day 8 (P=0.055). The
same method was used to predict the total anti-emetic
response in the delayed phase (i.e. no delayed emesis on any
day) and resulted in the following statistically significant
predictors: anti-emetic treatment with dexamethasone
(P=0.016), minimal tumour burden (P=0.021), low neuroti-
cism (P=0.03) and no previous history of motion sickness
(P=0.033). Among patients with large tumour burden 70.7%
experienced delayed emesis compared with 46.7% of those
with minimal tumour burden [RP 1.5 (1.1-2.1)]. The analysis
of total anti-emetic response relies actually on days 1 to 4
since no patient had her first day of delayed emesis later than
day 4.
Effects on nausea
Significantly more patients with large tumour burden
reported nausea on the chemotherapy day compared with
those with minimal tumour burden. The ratio of proportions
adjusted for age and anti-emetic treatment was 2.0 (1.0-4.1).
In the delayed phase (days 1 - 14) no significant association
was seen.
The overall effect of age on nausea during the monitoring
period is presented in Figure 3. From about 1 week after the
chemotherapy and onwards an increasing trend for more
frequent delayed nausea in older (>55 years) patients was
observed. For days 9-13, ratios of proportions adjusted for
tumour burden and anti-emetic treatment were 1.2-1.3 with
the 95% confidence interval separated from 1.0. This pattern
was evident primarily in patients with large tumour burden
(Figure 4). In this group, ratios of proportions adjusted for
anti-emetic treatment reached significance for day 7 [RP 1.7
(1.1-2.6)], day 9 [RP 1.5 (1.2-2.0)], day 10 [RP 1.5 (1.1-
1.9)], day 11 [RP 1.5 (1.2-2.0)], day 12 [RP 1.3 (1.1-1.6)]
and day 13 [RP 1.4 (1.1-1.8)]. In patients with minimal
tumour burden, no significant association between age and
nausea was observed during the study days.
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The logistic regression analyses confirmed that tumour
burden predicted nausea on the chemotherapy day (P= 0.013)
but not in the delayed phase. Age predicted nausea on days
9-12 (P<0.05). In the analysis using the total anti-emetic
response as the outcome (i.e. no delayed nausea on any day),
history of motion sickness was the only significant predictor
variable (P=0.018). Only 18 of the 101 participating patients
totally escaped from delayed nausea and 17 of these lacked
the previous history of motion sickness. The analysis of total
anti-emetic response describes what happens during days 1 -5
since no patient had her first day of delayed nausea later than
day 5.
Interaction between tumour burden and age
To illustrate interaction between tumour burden and age
further we compared patients with both the risk factors (i.e.
tumour burden >2 cm and age >55 years) with those with
none. Patients with only one of the two characteristics were
treated as one group. The results are presented in Figure 5
(emetic episodes) and Figure 6 (nausea). In both cases the
group with large residual tumour burden and higher age
clearly differs from the other two groups. The group with
only one of the risk factors shows a greater resemblance to
those with no risk factor than those with two.
Symptoms in the preceding week
The overall rating levels concerning the functional status
during the week preceding the chemotherapy were similar to
those obtained in a previous study with ovarian cancer
patients (Fiirst et al., 1992). However, the results indicated a
more compromised well-being for the patients with large
residual tumour burden compared with those with minimal
tumour burden (Table II). Significant differences were found
for vomiting, appetite, fatigue, general well-being and
(nearly significantly) strength. The patients with large
tumour burden were also less satisfied with the information
they received concerning their illness and its treatment. We
also analysed nausea and vomiting concerning the pure
prevalence by dichotomising the ratings in 'not bothered at
all' (VAS =0) and 'bothered' (VAS 1-100). Vomiting but
not nausea was more common in patients with large
compared with minimal tumour burden (vomiting, X2 =7.3,
P<0.01; nausea, X2=0.1, NS). Age was not related to
nausea and vomiting during the prechemotherapy period but
the older patients complained more about lack of strength
and difficulties in relaxation when compared with the
younger ones (Table II).
Table 2 Functional status during the week preceding the chemotherapy start
Tumour size Age
Variable <2 cm >2 cm P <55 years >55 years P
Nausea 8.8 10.6 >0.10 11.4 7.7 >0.10
Vomiting 2.0 6.7 0.014 2.8 4.9 >0.10
Pain 19.3 26.1 >0.10 20.2 23.9 >0.10
Lack of appetite 19.6 32.5 0.014 23.6 23.0 >0.10
Fatigue 33.4 45.9 0.017 33.8 43.0 0.076
Lack of strength 33.5 43.8 0.053 31.4 43.9 0.015
Difficulties in physical activity 23.4 31.5 0.084 24.2 29.1 >0.10
Feeling down 26.8 36.8 0.069 30.0 31.8 >0.10
Anger 23.1 30.2 >0.10 28.6 23.3 >0.10
Anxiety 37.3 42.1 >0.10 38.6 39.9 >0.10
Difficulties in relaxation 35.1 44.6 0.080 33.2 44.6 0.032
Difficulties in concentration 28.6 36.8 0.086 30.7 33.1 >0.10
Sleeping disorders 47.5 51.5 >0.10 49.2 48.7 >0.10
Disturbed family interaction 8.1 7.5 >0.10 9.0 6.7 >0.10
Disturbed other social interaction 15.7 17.1 >0.10 15.6 16.9 >0.10
Unsatisfied with information 8.5 16.0 0.038 12.3 10.7 >0.10
Lack of general well-being 41.9 51.9 0.037 43.8 48.0 >0.10
Mean ratings on a 100mm visual analogue scale forpatients categorised by the diameter ofthe greatest residual tumour (<2cm vs >2cm) and by
age (<55 years vs> 55 years). Low ratings correspond to unaffected well-being.Impact of tumour burden on emesis
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Discussion
Our results indicate an association between residual tumour
burden and chemotherapy-induced nausea and vomiting.
Thus, patients with tumour burden >2 cm in greatest
diameter compared with those with minimal tumour burden
reported more frequent emetic episodes in the delayed phase
and also, somewhat less articulated, in the acute phase. They
experienced more often acute but not delayed nausea.
Compared with younger ones, older patients reported more
frequent nausea during the second week after the chemother-
apy. They also tended to have more frequent emetic episodes
during the first days of the chemotherapy cycle. The anti-
emetic response for delayed emesis (no delayed emesis) was
predicted by anti-emetic treatment with dexamethasone,
minimal tumour burden, low neuroticism and the lack of
history of motion sickness. Likewise, the anti-emetic response
for delayed nausea was predicted by the lack of history of
motion sickness.
There may be several co-existing factors explaining our
results. The majority of patients categorised as having large
residual tumour burden had an intra-abdominal tumour
> 10 cm in greatest diameter. Hypothetically such a tumour
mass may exert a mechanical pressure on the gut leading to
nausea and vomiting. Alternatively, spontaneous or che-
motherapy-induced tumour necrosis may cause a release of
substances (e.g. prostaglandins or cytokines) from the tumour
and influence nausea and vomiting (Andrews and Davis,
1993).
During the week preceding the chemotherapy the patients
with large residual tumour burden reported vomiting
significantly more often accompanied by loss of appetite
and strength, increased fatigue and generally inferior well-
being compared with patients with minimal tumour burden.
Hypothetically, this could be explained by the above-
mentioned mechanisms. As demonstrated in Figures 1 and
2 it seems that in the group of patients with large residual
tumour, the rate ofcomplete response does not improve after
day 9. This observed difference may to some extent reflect
prechemotherapy differences. However, it should be pointed
out that none of the patients experienced vomiting 24 h
before the start of the chemotherapy.
Older patients, particularly those with large residual
tumour burden, reported more frequent side-effects in the
delayed phase compared with younger patients. This is in
contrast to some previous studies showing an inverse
relationship between age and acute nausea and vomiting
(Tonato et al., 1991). The association between age and emesis
has not been thoroughly studied during the delayed phase.
To our knowledge no previous report has shown age
differences in delayed nausea or vomiting (Carmichael et
al., 1994; du Bois et al., 1992; Gandara et al., 1993; Italian
Group for Antiemetic Research, 1994; Kaizer et al., 1994;
Lindley et al., 1989; Roila et al., 1991). Interestingly, in more
recent studies, the evidence provided for an inverse relation-
ship between age and emesis in the acute phase has not been
consistent (de Wet et al., 1993; Heron et al., 1994; Italian
Group for Antiemetic Research, 1993; Ruff et al., 1994). This
may be related to the introduction of new anti-emetic
regimens. The mechanisms mediating the effect of age on
nausea and vomiting are not known. However, the
association is most likely multifactorially determined and
hence modified by several variables.
The combined aggravating effects of tumour burden and
age in the delayed phase may also be conceived of as a more
general age-dependent problem of recovery (Erschler and
Balducci, 1994). In general, elderly patients recover more
slowly after, for example, surgery or an injury (Artinian et
al., 1993; Pennings et al., 1993). The effect of cancer
treatment is also less favourable for older patients compared
with younger patients (Alberts et al., 1993). As demonstrated
in Figure 4 older patients with tumour seem to recover more
slowly from the chemotherapy compared with younger
patients (slope of the curve is less steep for older patients).
In conclusion, monitoring nausea and vomiting up to 2
weeks after chemotherapy revealed that while the delayed
symptoms decreased exponentially during the first week, there
was practically no further improvement during the second
week. The results suggest that older patients with large
residual tumour burden are at increased risk of this
'persistent' delayed nausea and vomiting. Also, earlier in
the delayed phase these patients suffered from more frequent
emetic episodes. Large tumour burden was associated with
compromised well-being already before the treatment started.
This is decremental since persistent nausea and vomiting may
lead to a descending spiral with further worsening of
functional status (O'Brien et al., 1993). The impact of
'persistent' delayed nausea on delivered dose intensity of
chemotherapy given with a curable intent and well-being
when given in a palliative setting warrants further attention.
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